ArticleAntimicrobial agents and chemotherapy2004
Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections.Expert review of anti-infective therapy · 2013Pooled it
- Trial
- Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy.The Journal of infectious diseases · 2012Trial
- A repetitive nucleotide insertion in the rplV gene is associated with in vitro resistance to azithromycin in Rickettsia typhi.PLoS neglected tropical diseases · 2026Article
- Putative azithromycin resistance mutations inAntimicrobial agents and chemotherapy · 2026Article
- Repurposing epetraborole to combatAntimicrobial agents and chemotherapy · 2026Article
- Article
- Azithromycin alters the microbiome composition, function and resistome in women with Chlamydia trachomatis infections.NPJ biofilms and microbiomes · 2025Article
- Article
- Phenotypic and Genotypic Antimicrobial Susceptibility Testing ofAntibiotics (Basel, Switzerland) · 2023Article
- Review
- Mechanism of action, resistance, synergism, and clinical implications of azithromycin.Journal of clinical laboratory analysis · 2022Review
- Identification and characterization of mixed infections ofFrontiers in microbiology · 2022Article
- Rhein inhibitsFrontiers in public health · 2022Article
- Direct assessment of possible mutations in the 23S rRNA gene encoding macrolide resistance in Chlamydia trachomatis.PloS one · 2022Article
- An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.Annals of clinical microbiology and antimicrobials · 2021Review
- Chlamydial clinical isolates show subtle differences in persistence phenotypes and growthAccess microbiology · 2021Article
- The macrolide antibiotic renaissance.British journal of pharmacology · 2017Review
- Comprehensive global genome dynamics ofGenome research · 2017Article
- Resistance to Macrolide Antibiotics in Public Health Pathogens.Cold Spring Harbor perspectives in medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For six clinical isolates of Chlamydia trachomatis, in vitro susceptibility to erythromycin, azithromycin, and josamycin has been determined. Four isolates were resistant to all the antibiotics and had the mutations A2058C and T2611C (Escherichia coli numbering) in the 23S rRNA gene. All the isolates had mixed populations of bacteria that did and did not carry 23S rRNA gene mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.